Glauber Pereira, MD
Pulmonary Disease · Rogers, ARNPI 1841610037
Payments from drug & device makers
What this record shows
This record is dominated by education: $7,000 of the $11,351 with a category attached, or 61.7%. Intuitive Surgical accounts for 79.8% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2024 at $9,562 and has fallen 95.8% since, to $401 in 2025.
Across 133 payments — averaging $85.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$9K
- Boehringer Ingelheim$337
- GSK$211
- Merck$188
- United Therapeutics Corporation$132
- Grifols USA, LLC$130
- plus $1K from 20 others
What the payments were for
- Travel & lodging$1,83416%
- Food & beverage$2,51722%
- Education$7,00062%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 23 | $9,056 |
| Boehringer Ingelheim | 19 | $337 |
| GSK | 12 | $211 |
| Merck | 9 | $188 |
| United Therapeutics Corporation | 5 | $132 |
| Grifols USA, LLC | 5 | $130 |
| AstraZeneca(2 entities) | 9 | $128 |
| Sanofi | 5 | $126 |
| Regeneron Healthcare Solutions, Inc. | 4 | $107 |
| Mallinckrodt Hospital Products Inc. | 4 | $101 |
| AbbVie | 5 | $99 |
| La Jolla Pharmaceutical Company | 4 | $85 |
| Philips North America LLC | 4 | $82 |
| Gilead | 4 | $73 |
| Baxter Healthcare | 2 | $62 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $58 |
| Advanced Respiratory, Inc | 3 | $55 |
| Pfizer | 3 | $52 |
| Inari Medical, Inc. | 2 | $50 |
| Aimmune Therapeutics, Inc. | 1 | $43 |
| ANI Pharmaceuticals, Inc. | 2 | $40 |
| Amgen | 2 | $35 |
| Beckman Coulter, Inc. | 1 | $31 |
| Chiesi USA, Inc. | 1 | $29 |
| Inspire Medical Systems, Inc. | 1 | $21 |
| Mylan Specialty L.p. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$8,774
How this compares
$11,351 in reported general payments places this provider in the 85th percentile of 102 pulmonary disease providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 43 | $566,460 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 99 | $79,287 |
| Breo ElliptaFluticasone/Vilanterol | 44 | $19,823 |
| Ambrisentan | 12 | $15,169 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 28 | $13,554 |
| Spiriva RespimatTiotropium Bromide | 13 | $11,300 |
| Advair HfaFluticasone Propion/Salmeterol | 28 | $10,329 |
| Incruse ElliptaUmeclidinium Bromide | 29 | $9,800 |
| Roflumilast | 59 | $7,568 |
| SymbicortBudesonide/Formoterol Fumarate | 25 | $7,525 |
| DuleraMometasone/Formoterol | 19 | $6,051 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 11 | $4,671 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 23 | $3,736 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 19 | $2,431 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 65 | $1,803 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $337 | $591,31484 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $211 | $108,910172 claims |
| AstraZenecaSymbicort, Bevespi Aerosphere | $128 | $12,19636 claims |
| MerckDulera | $188 | $6,05119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 102 pulmonary disease providers in Arkansas.
Other pulmonary disease in Rogers
- Daniel PaulRogers$244K
- Jason McKinneyRogers$86K
- Penchala MittadodlaRogers$21K
- Junaid KhanRogers$6K
- Kevin MeredithRogers$5K
- Amer RazaRogers$5K
- Ladly AbrahamConway$371K
- Arturo MeadeFort Smith$67K
- Nikhil MeenaLittle Rock$63K
- Mark SiffordJonesboro$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.